Penny stocks are high-risk, high-reward investment vehicles for investors looking to take advantage of heightened volatility in the market. One factor that can attract investors with a high appetite for risk is the possibility of generating significant returns in a short period of time. With proper due diligence and a solid risk management strategy, it is possible to generate above-average returns from penny stocks.

The first step in investing in penny stocks is to conduct thorough research on the company. The goal is to understand the risks and whether they align with the underlying investment strategy.

Momentum and trading volumes are two important factors that investors should keep a close eye on when looking to trade penny stocks. High trading volumes and momentum signal that more traders are trading the stock, making it easy to determine its likely direction. EPAZ, TSOI, HCNWF, and DPLS are the four penny stocks eliciting strong interest due to surging trading volumes and are likely to provide exciting trading opportunities in the coming days.

Epazz, Inc. (OTC: EPAZ) offers one of the most compelling risks-to-reward ratios thanks to its diversified core business that affirms its long-term prospects and growth metrics. The small-cap company has made a name for itself providing mission-critical drone technology that continues to elicit strong interest from the armed forces. In addition, it has diversified its footprint on the development of blockchain mobile apps as it also offers cloud-based business software solutions.

The stock is already up by more than 300% for the year and was up by more than 80% in March. Moreover, momentum around the stock is slowly building up, especially after the recent pullback from 2023 highs. The soaring momentum comes on the heels of traders taking note of the U.S. Air Force announcing plans to use drones developed by the company's spinoff, ZenaDrone 1000, for cargo delivery.

The ZenaDrone 1000 is a unique autonomous drone solution designed to enhance surveillance, inspection, and monitoring, also comes equipped with innovative software technology and machine learning systems, making it highly effective in various sectors, like farming, or security for example.

There are plans to enhance the drone's A.I. capabilities to enable autonomous navigation over unmapped terrains. The drones will also come with dual-use features, making them highly suited for commercial and military applications. It will also use the data captured by the cameras to provide an interactive and detailed 3D interactive environment.

The U.S. Air Force is to test the ZenaDrone 1000 platform on blood transport, among other things, in battlefield conditions. It will be the first time the company's technology is being used in a military environment. The milestone puts the Epazz a step closer to qualifying for a phase II Small Business Innovation Research (SBIR) grant to the tune of $1.2 million in non-dilutive funding for its cargo delivery solution.

The deal comes from the company showcasing and presenting its technology in front of the U.S. military as it continues to gain traction with the Air Force and the Army. The strong military interest could open up new revenue streams within the defense sector for the company.

CEO Shaun Passley, Ph.D., said, "We are excited to see ZenaDrone 1000 the subject of so much attention in multiple military branches. The Air Force clearly sees value in this platform and is pushing the envelope of new testing to find out the extent of its capabilities. We are anxious to receive critical feedback from the Air Force as we transition to mass production operations. We are currently in the process of evaluating a number of suitable sites while balancing the potential commercial uses. We also hope shareholders see how we are trying to move the technology forward through the use of nondilutive funding sources."

The company is to meet with the maintenance crew at the military airbase to determine how to integrate the ZenaDrone 1000 into operations. Additionally, it is in the process of registering several drones with the FAA as it also seeks to secure the necessary insurance.

Even as drones receive interest from various military branches in the US, ZenaDrone continues to explore multiple commercial uses of the technology. Equipped with artificial intelligence technology, the drones are well equipped for use in the oil and gas fields. In addition, they should elicit strong interest from the agriculture industries.

Banning Chinese drones within U.S. government installations presents a massive opportunity for ZenaDrone 1000. In addition, there is a growing need and demand for non-Chinese drones within government departments through the BlueUS program.

Epazz CEO Shaun Passkey has already confirmed that they are taking the necessary steps to become an official government contractor of drones. The filling of Phase 1 SBIR proposals presents an opportunity for the company to eye contracts worth up to $15 million over the next three years.

Epazz should continue to garner positive reviews as ZenaDrone 1000 attracts interest for use in various industries, including agriculture, oil and gas, civil engineering, and, most importantly, defense. Its state-of-the-art technology, competitive pricing, and rising demand set the company on course to diversify and strengthen its revenue streams. As momentum continues to build around the stock, Epazz is a must-pick for diversifying any investment portfolio.

Therapeutic Solutions International Inc. (OTCMKTS: TSOI) is another exciting momentum play that has started bottoming out after a long period of consolidation. The stock was up by over 20% last week from its all-time lows. The company's spinoff Campbell Neuroscience is a big player in developing immune modulatory agents used in treating cancers, Schizophrenia among other diseases.

Momentum has been building around the stock of the spinoff company announcing positive results from an ongoing CampbellCell stem cell treatment regimen. Latest trials have shown that CampbellCell administration resulted in the production of cytokine interleukin-4, needed to suppress schizophrenia development.

Schizophrenia is a significant cause of suicide and causes various immunological abnormalities. The CampbellCell is already showing tremendous potential in suppressing brain inflammation affirming its credential as a potential Schizophrenia treatment.

"Campbell Neurosciences is making substantial progress in development of a biomarker-based test for suicidal ideations which involves saliva based detection of inflammatory cytokines," said Dr. Thomas Ichim, President, and CEO of Campbell Neurosciences.

Another penny stock on the move is Hypercharge Networks Corp. (OTCQB: HCNWF), which finished on the green after rallying by more than 40% last week. The explosive action came when the leading provider of electric vehicle charging solutions announced a non-brokered provider placement of 4.7 million units priced at $1.05. The company expects gross proceeds of up to $5 million from the offering.

Hypercharge Network intends to use the net proceeds from the offering to expand its operations and fund marketing and investor relations. The funds will also aid in research and development as the company looks to accelerate E.V. adoption and enable a shift towards a carbon neutral economy. The company offers turnkey solutions to residual and commercial buildings, fleet operations, and other growing sectors.

As the electric vehicle revolution takes shape, demand for charging stations should continue to rise. Hypercharge Network stands to generate significant value by offering a robust public and private charging network across the country.

Darkpulse Inc. (OTCMKTS: DPLS) is another penny stock on the move after a long period of consolidation. Momentum is building up as the company inches a step closer to completing a business combination with Global System Dynamics, Inc. (Nasdaq: GSD). The company has already secured a one-month extension to complete the business merger after depositing $83.94K into GSDs trust account.

DarkPulse is a technology company. It leverages advanced laser-based monitoring systems to detect and monitor temperature, strains and stresses for advanced structural monitoring in smart cities. The push to merge with GSD is expected to further the company's plans to offer best in class infrastructure solutions for the massive end market.

Dennis O'Leary, Founder & Chief Executive Officer of DarkPulse stated, "I am pleased to report that GSD's Board of Directors has approved our request for an additional one-month extension to complete the business combination. We remain as committed as ever to completing the transaction with GSD in order to further invest in our mission to deliver best-in-class infrastructure solutions to a massive end market."

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. CaptalGainsReport 'CGR' (owned by RazorPitch Inc.) is responsible for the production and distribution of this content. CGR is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. CGR authors, contributors, or its agents, may be compensated for preparing research, video graphics, and editorial content. CGR has been compensated to produce content related to EPAZ. As part of that content, readers, subscribers, and webs are expected to read the full disclaimers and financial disclosure statement that can be found on our website.

CapitalGainsReport.com

CONTACT: Mark McKelvie

CapitalGainsReport

Editor

585 301 7700

.

(C) 2023 M2 COMMUNICATIONS, source M2 PressWIRE